High mobility group box-1: a potential therapeutic target for allergic rhinitis

Eur J Med Res. 2023 Oct 12;28(1):430. doi: 10.1186/s40001-023-01412-z.

Abstract

Allergic rhinitis (AR) is a prevalent chronic inflammatory disease of the nasal mucosa primarily characterized by symptoms, such as nasal itching, sneezing, runny nose, and nasal congestion. It has a high recurrence rate and low cure rate, with a lack of effective drugs for treatment. The current approach to management focuses on symptom control. High mobility group box-1 (HMGB1) is a highly conserved non-histone protein widely present in the nucleus of eukaryotes. It is recognized as a proinflammatory agent, and recent studies have demonstrated its close association with AR. Here, we will elaborate the role and mechanism of HMGB1 in AR, so as to reveal the potential value of HMGB1 in the occurrence and development of AR, and provide a new target for clinical research on the treatment of AR.

Keywords: Allergic rhinitis; High mobility group box-1; Mechanism; Target.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • HMGB1 Protein*
  • Humans
  • Rhinitis, Allergic* / drug therapy

Substances

  • HMGB1 Protein